BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics ALRNa chemoprotective oncology company committed to making chemotherapy safer, more effective to save more patient lives, today announced that a pre-recorded company presentation by Manuel Aivado, MD, Ph.D., President and Chief Executive Officer, will be available on-demand at the HC Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 7:00 a.m. ET.
The presentation will be available on the Investors & Media section of the Company’s website at ailerrx.com. A replay of the webcast will be archived on the Aileron website for approximately 30 days after the presentation.
About Aileron Therapeutics
Aileron is a clinical-stage oncology chemoprotection company committed to making chemotherapy safer and therefore more effective to save more patient lives. ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor, is designed to activate p53, which in turn upregulates p21, a known cell replication cycle inhibitor. ALRN-6924 is the only known chemoprotective agent in clinical development that employs a biomarker strategy in which we are solely focused on treating patients with p53 mutant cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells. As a result, healthy cells are spared from destruction by chemotherapy while chemotherapy continues to kill cancer cells. By reducing or eliminating several chemotherapy-induced side effects, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Improved tolerability may result in fewer dose reductions or chemotherapy delays and the potential for improved efficacy. Our vision is to provide chemoprotection to all patients with p53 mutant cancer, which accounts for approximately 50% of cancer patients, regardless of the type of cancer or…
